Cellectis S.A. announced today that they entered into an agreement with Shire Pharmaceuticals, by which Cellectis will grant Shire a worldwide non-exclusive commercial license relating to it site-directed genome engineering technologies for creating and developing genetically engineered cells to produce certain gene activated biopharmaceuticals. Financial terms and conditions of the agreement were not disclosed.